Zacks.com on MSN2d
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
AnaptysBio price target raised to $51 from $40 at Wells Fargo
Wells Fargo raised the firm’s price target on AnaptysBio (ANAB) to $51 from $40 and keeps an Overweight rating on the shares. The firm believes ...
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for ...
Anaptys surges as arthritis therapy succeeds in mid-stage trial
AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint
AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...
The Pharma Letter2d
AnaptysBio rockets on rosnilimab data
Shares in AnaptysBio, a San Diego-based biotech focused on delivering innovative immunology therapeutics, was trading 19% ...
AnaptysBio Shares Surge 37% After Mid-Stage Rheumatoid Arthritis Trial Meets Primary Goal
AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.
news.stocktradersdaily12h
When the Price of (ANAB) Talks, People Listen
GET MORE AI-GENERATED SIGNALS: February 15, 2025, 04:28 am ET, BY Thomas H. Kee Jr- Editor, Stock Traders Daily| Editor: ...
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral
H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock. According to ...